HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA May Adopt Safety Guidelines Based On EU Model - CHIC Meeting

This article was originally published in The Rose Sheet

Executive Summary

FDA's Office of Cosmetics & Colors may consider cosmetic safety substantiation guidelines based on a European Union model following the Cosmetic Harmonization and International Cooperation meeting in Washington, D.C. May 8-10.

You may also be interested in...



FDA Cosmetics Safety Guidelines Could Create New Hurdles, Attorney Says

The adoption of cosmetics safety substantiation guidelines, currently under consideration by FDA's Office of Cosmetics & Colors, may inadvertently create additional regulatory hurdles, according to food and drug attorney Georgia Ravitz of Arent, Fox, Kintner, Plotkin & Kahn.

FDA Cosmetics Safety Guidelines Could Create New Hurdles, Attorney Says

The adoption of cosmetics safety substantiation guidelines, currently under consideration by FDA's Office of Cosmetics & Colors, may inadvertently create additional regulatory hurdles, according to food and drug attorney Georgia Ravitz of Arent, Fox, Kintner, Plotkin & Kahn.

U.S./EU Cosmetic "Memo Of Cooperation" May Expand To Canada, Japan

The U.S./EU cosmetics "memorandum of cooperation" may be expanded to include Japan and Canada to provide the legal structure for information exchange and confidentiality agreements between participants.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel